Fisher B, Constantino JP, Wickerham DL.
et al. Tamoxifen for prevention of breast cancer: report of the National Surgical
Adjuvant Breast and Bowel Project PI Study. J Natl Cancer Inst.1998;90:1371-1388.
Gail MH, Costantino JP, Bryant J.
et al. Weighing the risks and benefits of tamoxifen treatment for preventing
breast cancer. J Natl Cancer Inst.1999;91:1829-1846.
Miki Y, Swensen J, Shattuck-Eidens D.
et al. A strong candidate for the breast and ovarian cancer susceptibility
gene BRCA1. Science.1994;266:66-71.
Wooster R, Bignell G, Lancaster J.
et al. Identification of the breast cancer susceptibility gene BRCA2. Nature.1995;378:789-792.
Welcsh PL, King M-C. BRCA1 and BRCA2 and
the genetics of breast and ovarian cancer. Hum Mol Genet.2001;10:705-713.
Loman N, Johannsson O, Bendahl P-O, Borg A, Ferno M, Olsson AH. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown
susceptibility genes. Cancer.1998;83:310-319.
Klemp J, Brady D, Frank TS, Kimler BF, Fabian CJ. Incidence of BRCA1/2 germ line alterations
in a high-risk cohort participating in a phase II chemoprevention trial. Eur J Cancer.2000;36:1209-1214.
Johannsson OT, Idvall I, Anderson C.
et al. Tumour biological features of BRCA1-induced
breast and ovarian cancer. Eur J Cancer.1997;33:362-371.
Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol.1999;17:3653-3663.
Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers
in carriers of BRCA1 or BRCA2
mutations and sporadic cases. Lancet.1997;349:1505-1510.
Gail MH, Brinton LA, Byar DP.
et al. Projecting individualized probabilities of developing breast cancer
for white females who are being examined annually. J Natl Cancer Inst.1989;81:1879-1886.
Smith TM, Lee M, Szabo CI.
et al. Complete genomic sequence and analysis of 117 kb of human DNA containing
the gene BRCA1. Genome Res.1996;6:1029-1049.
Ewing B, Green P. Base-calling of automated sequencer traces using Phred, II: error probabilities. Genome Res.1998;8:186-194.
Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using Phred, I: accuracy
assessment. Genome Res.1998;8:175-185.
Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide
substitutions using fluorescence-based resequencing. Nucleic Acids Res.1997;25:2745-2751.
Lee MK, Lynch ED, King M-C. SeqHelp: a program to analyze molecular sequences utilizing common
computational resources. Genome Res.1998;8:306-312.
Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res.1998;8:195-202.
Mazoyer S, Dunning AM, Serova O.
et al. A polymorphic stop codon in BRCA2. Nat Genet.1996;14:253-254.
Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA.1998;279:915-921.
Malone KE, Daling JR, Neal C.
et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer.2000;88:1393-1402.
Peto J, Collins N, Barfoot R.
et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst.1999;91:943-949.
NYBCS Collaborative Group. Breast and ovarian cancer risks among women with BRCA1 and BRCA2 mutations in the New York
Breast Cancer Study. Am J Hum Genet.2001;68:292.
Warner E, Foulkes W, Goodwin P.
et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women
with breast cancer. J Natl Cancer Inst.1999;91:1241-1247.
Robson M, Gilewski T, Haas B.
et al. BRCA-associated breast cancer in young women. J Clin Oncol.1998;16:1642-1649.
Karp SE, Tonin PN, Begin LR.
et al. Influence of BRCA1 mutations on nuclear grade
and estrogen receptor status in breast cancers in Ashkenazi Jewish women. Cancer.1997;80:435-441.
Verhoog LC, Brekelmans CTM, Seynaeve C.
et al. Survival and tumour characteristics of breast-cancer patients with
germline mutations of BRCA1. Lancet.1998;351:316-321.
Verhoog LC, Brekelmans CT, Seynaeve C.
et al. Survival in hereditary breast cancer associated with germline mutations
of BRCA2. J Clin Oncol.1999;17:3396-3402.
Borg A, Dorum A, Heimdal K, Maehle L, Hovig E, Moller P. BRCA1 1675delA and 1135insA account for one
third of Norwegian familial breast-ovarian cancer and are associated with
later disease onset than less frequent mutations. Dis Markers.1999;15:79-84.
Wagner TM, Moslinger RA, Muhr D.
et al. BRCA1-related breast cancer in Austrian breast
and ovarian cancer families: specific BRCA1 mutations
and pathological characteristics. Int J Cancer.1998;77:354-360.
Armes JE, Trute L, White D.
et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers:
a population-based study. Cancer Res.1999;59:2011-2017.
Hall JM, Lee MK, Morrow J, Newman B, Huey B, King M-C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science.1990;250:1684-1689.
Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst.1999;91:1310-1316.
Moslehi R, Chu W, Karlan B.
et al. BRCA1 and BRCA2 mutation
analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet.2000;66:1259-1272.
Meijers-Heijboer H, van Geel B, van Putten WL.
et al. Breast cancer after prophylactic bilateral mastectomy in women with
a BRCA1 or BRCA2 mutation. N Engl J Med.2001;345:159-164.
Rebbeck TR, Levin AM, Eisen A.
et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst.1999;91:1475-1479.
Fisher B, Costantino J, Redmond C.
et al. A randomized clinical trial evaluating tamoxifen in the treatment of
patients with node-negative breast cancer who have estrogen-receptor-positive
tumors. N Engl J Med.1989;320:479-484.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet.1998;351:1451-1467.
Narod SA, Brunet JS, Ghadirian P.
et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control